Clinical trials: Peptide Receptor Radionuclide Therapy
- Condition Peptide Receptor Radionuclide Therapy
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma
Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs
This is a multicenter, open-label, single-arm study to evaluate the safety and dosimetry of Lutathera in adolescent patients 12 to <18 years old with somatostatin receptor positive GEP-NETs and PPGLs.
- Conditions
- Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma, Paraganglioma
- Trial name
- NETTER-P (NCT04711135)
- Testing
- Lutetium [177Lu] oxodotreotide/dotatate
- Where
- 7 sites in United States, France and 3 more
- Volunteers
- 11 people
- Sponsor
- Advanced Accelerator Applications
Gastroenteropancreatic Neuroendocrine Tumors
Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients
The purpose of the study was to evaluate the effect of arginine/lysine solution administration on serum potassium levels. A systematic assessment of serum potassium levels was performed during infusion and up to 24 hours post…
- Trial name
- NCT04524442
- Testing
- arginine/lysine
- Where
- 7 sites in Italy, Netherlands and 2 more
- Volunteers
- 42 people
- Sponsor
- Advanced Accelerator Applications
Neuroendocrine Tumors
Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients
The purpose of the study is to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive…
- Trial name
- COMPETE (NCT03049189)
- Testing
- 177Lu-edotreotide PRRT, Everolimus, Amino-Acid Solution
- Where
- 52 sites in United States, Australia and 12 more
- Volunteers
- 324 people
- Sponsor
- ITM Solucin GmbH